Article Text

Download PDFPDF
Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade
  1. Juergen Rech1,
  2. Monika Ronneberger1,
  3. Matthias Englbrecht1,
  4. Stephanie Finzel1,
  5. Julia Katzenbeisser1,
  6. Karin Manger2,
  7. Bernhard Manger1,
  8. Georg Schett1
  1. 1Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
  2. 2Rheumatology Outpatient Clinic, Bamberg, Germany
  1. Correspondence to Dr Juergen Rech, Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Ulmenweg 18, Erlangen 91054, Germany; juergen.rech{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown aetiology.1 Based on the substantial acute phase responses observed in AOSD, we hypothesised that blockade of the interleukin 6R (IL-6R), neutralising the induction of the acute phase response by IL-6, could be a useful treatment in multidrug-resistant AOSD. We here report on three patients with AOSD who were refractory to standard treatment and cytokine blockade with anakinra and tumour necrosis factor (TNF) blockers and were subjected to treatment with tocilizumab. The characteristics of these three patients are summarised in table 1.

View this table:
Table 1

Characteristics of patients

Patient 1

A 19-year-old woman was first diagnosed with AOSD in July 2006. Prednisone therapy was started, but multiple relapses occurred during the following 2 years requiring …

View Full Text


  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Competing interests None.